RxDoctor Payments Data

Colleen Ohene-Agyei, PA

Physician Assistant · Kingston, NYNPI 1386654655

Payments from drug & device makers

$3,078in general payments, 2019–2025

Across 40 payments — averaging $76.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Incyte Corporation$205
  • Sanofi$180
  • Takeda Pharmaceuticals U.S.A., Inc.$165
  • Johnson & Johnson$157
  • AstraZeneca$131
  • plus $230 from 6 others

What the payments were for

  • Food & beverage$66622%
  • Education$41714%
  • Other$1,99565%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,078 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$19,287
Medicare patients
112
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib58$773,427
IbrancePalbociclib43$729,472
RevlimidLenalidomide23$390,352
XtandiEnzalutamide15$218,586
LynparzaOlaparib12$203,791
CalquenceAcalabrutinib Maleate13$200,810
VenclextaVenetoclax18$175,537
VerzenioAbemaciclib14$172,442
NubeqaDarolutamide15$161,975
Abiraterone Acetate22$136,883
PomalystPomalidomide12$65,891
EliquisApixaban28$39,833
OrgovyxRelugolix12$30,778
Exemestane30$5,407
Anastrozole157$3,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza, Calquence$131$404,60125 claims
Astellas Pharma US IncXtandi$19$218,58615 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$14$65,89112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →